HPV infection found to increase risk of lung cancer
the ONA take:
According to a new study published in the Journal of Clinical Virology, researchers have found that there is a strong association between lung tissue with human papillomavirus (HPV) infection, particularly HPV subtypes 16 and 18, and lung cancer. For the meta-analysis, the researchers searched various databases through March 2014 and identified nine studies that it total included 1,094 lung cancer cases and 484 non-cancer cases.
Statistical analyses showed that HPV infection was associated with lung cancer (Odds Ratio [OR] = 5.67, 95% CI: 3.09-10.40, P <0.001). Researchers also found that HPV subtypes 16 and 18 were similarly associated with lung cancer (OR = 6.02, 95% CI: 3.22-11.28, P <0.001). Furthermore, HPV 16 and 18 were strongly associated with lung squamous cell carcinoma (SCC) (OR = 9.78, 95% CI: 6.28-15.22, P <0.001), which was three times greater than with lung adenocarcinoma (OR = 3.69, 95% CI: 0.99-13.71, P = 0.052).
The findings suggest that HPV subtypes 16 and 18 infection significantly elevates the risk for developing SCC, indicating that there may be causal pathogenesis association between HPV and lung cancer.
Researchers have found that there is a strong association between lung tissue with HPV.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|